Trial Watch: Immune Checkpoint Blockers for Cancer Therapy

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2017 Nov 18

PMID 29147629

Citations 42

Authors

Claire Vanpouille-Box

Claire Lhuillier

Lucillia Bezu

Fernando Aranda

Takahiro Yamazaki

Oliver Kepp

Jitka Fucikova

Radek Spisek

Sandra Demaria

Silvia C Formenti

Laurence Zitvogel

Guido Kroemer

Lorenzo Galluzzi

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications. Although considerable attention persists around the inhibition of cytotoxic T lymphocyte-associated protein 4 (CTLA4) and programmed cell death 1 (PDCD1, best known as PD-1) signaling, several other co-inhibitory T-cell receptors are being evaluated as potential targets for the development of novel ICBs. Moreover, substantial efforts are being devoted to the identification of biomarkers that reliably predict the likelihood of each patient to obtain clinical benefits from ICBs in the absence of severe toxicity. Tailoring the delivery of specific ICBs or combinations thereof to selected patient populations in the context of precision medicine programs constitutes indeed a major objective of the future of ICB-based immunotherapy. Here, we discuss recent preclinical and clinical advances on the development of ICBs for oncological indications.

Citing Articles

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.

Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y Mol Cancer. 2024; 23(1):261.

PMID: 39574178 PMC: 11580516. DOI: 10.1186/s12943-024-02165-x.

Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy.

Zhou B, Yang Y, Kang Y, Hou J, Yang Y Cell Commun Signal. 2024; 22(1):66.

PMID: 38273373 PMC: 10809660. DOI: 10.1186/s12964-023-01384-x.

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.

Guo D, Ye L, Wu W, Yu X, Jin K Acta Biochim Biophys Sin (Shanghai). 2023; 55(6):923-937.

PMID: 37021976 PMC: 10326418. DOI: 10.3724/abbs.2023045.

The role of LncRNAs in tumor immunotherapy.

Pan X, Li C, Feng J Cancer Cell Int. 2023; 23(1):30.

PMID: 36810034 PMC: 9942365. DOI: 10.1186/s12935-023-02872-3.

Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment.

Zhu Y, Li X, Wang L, Hong X, Yang J Front Endocrinol (Lausanne). 2022; 13:988295.

PMID: 36046791 PMC: 9421293. DOI: 10.3389/fendo.2022.988295.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Maker A . Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology. 2016; 5(1):e1069937. PMC: 4760328. DOI: 10.1080/2162402X.2015.1069937. View

Ganesan A, Clarke J, Wood O, Garrido-Martin E, Chee S, Mellows T . Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017; 18(8):940-950. PMC: 6036910. DOI: 10.1038/ni.3775. View

Ralph C, Elkord E, Burt D, ODwyer J, Austin E, Stern P . Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010; 16(5):1662-72. DOI: 10.1158/1078-0432.CCR-09-2870. View

Buque A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman W . Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology. 2016; 5(6):e1149674. PMC: 4938376. DOI: 10.1080/2162402X.2016.1149674. View

DAngelo S, Shoushtari A, Keohan M, Dickson M, Gounder M, Chi P . Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2016; 23(12):2972-2980. PMC: 5486863. DOI: 10.1158/1078-0432.CCR-16-2349. View

Shin D, Ribas A . The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr Opin Immunol. 2015; 33:23-35. DOI: 10.1016/j.coi.2015.01.006. View

Textor S, Bossler F, Henrich K, Gartlgruber M, Pollmann J, Fiegler N . The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology. 2016; 5(7):e1116674. PMC: 5007025. DOI: 10.1080/2162402X.2015.1116674. View

Dorand R, Nthale J, Myers J, Barkauskas D, Avril S, Chirieleison S . Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016; 353(6297):399-403. PMC: 5051664. DOI: 10.1126/science.aae0477. View

10.

Kroemer G, Galluzzi L, Zitvogel L, Fridman W . Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?. Oncoimmunology. 2015; 4(7):e1058597. PMC: 4485723. DOI: 10.1080/2162402X.2015.1058597. View

11.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

12.

Weber J, Yang J, Atkins M, Disis M . Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015; 33(18):2092-9. PMC: 4881375. DOI: 10.1200/JCO.2014.60.0379. View

13.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

14.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

15.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

16.

Martinez-Sanchez M, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros N . Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2016; 5(4):e1093721. PMC: 4839374. DOI: 10.1080/2162402X.2015.1093721. View

17.

Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S . Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology. 2015; 4(5):e1001236. PMC: 4485845. DOI: 10.1080/2162402X.2014.1001236. View

18.

Sharma P, Wagner K, Wolchok J, Allison J . Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011; 11(11):805-12. PMC: 3426440. DOI: 10.1038/nrc3153. View

19.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I . Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015; 4(4):e1008866. PMC: 4485780. DOI: 10.1080/2162402X.2015.1008866. View

20.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View